AbVacc

Executive Summary

AbVacc is a private biotechnology company based in Rockville, MD, founded in 2008. The company specializes in developing monoclonal antibodies (mAbs) derived from macaques or humans, as well as engineered fusion mAbs with host-cell targeting capabilities. Its platform leverages natural immune diversity and advanced engineering to create potent, specific immunotherapies for infectious diseases and oncology. Despite operating for over 15 years, AbVacc has maintained a low public profile, with no disclosed pipeline, clinical trials, or regulatory milestones. This suggests a focus on early-stage research and development. The company's approach holds potential for targeting difficult antigens, but the absence of transparent progress data limits visibility into its current stage and value inflection points.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for lead fusion mAb candidate40% success
• Q2 2027IND filing for lead mAb targeting host-cell antigens30% success
• Q3 2026Strategic partnership or licensing deal for platform technology20% success